Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: manning geist bl. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY, Manning-Geist BL, Ehmann S, Lavery JA, Luardo C, Praiss A, Iasonos A, Sonoda Y, Grisham RN, Liu YL, Broach V, Zivanovic O, Long Roche K, Gardner GJ, Chi DS. Sia TY, et al. Among authors: manning geist bl. Gynecol Oncol. 2023 Sep;176:69-75. doi: 10.1016/j.ygyno.2023.07.006. Epub 2023 Jul 14. Gynecol Oncol. 2023. PMID: 37454565
The highs and lows of serous ovarian cancer.
Grisham RN, Manning-Geist BL, Chui MH. Grisham RN, et al. Among authors: manning geist bl. Cancer. 2023 Sep 1;129(17):2613-2620. doi: 10.1002/cncr.34903. Epub 2023 Jun 27. Cancer. 2023. PMID: 37366225 Review.
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D, Kravetz S, Laface I, Rasalan-Ho T, Qi J, Wong P, Sabbatini PJ, O'Cearbhaill RE. Manning-Geist BL, et al. Cancers (Basel). 2023 Feb 25;15(5):1458. doi: 10.3390/cancers15051458. Cancers (Basel). 2023. PMID: 36900251 Free PMC article.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, Roche KL, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, Chi DS, Aghajanian C, Feldman DR. Liu YL, et al. Among authors: manning geist bl. Gynecol Oncol. 2023 Mar;170:93-101. doi: 10.1016/j.ygyno.2022.12.022. Epub 2023 Jan 18. Gynecol Oncol. 2023. PMID: 36669327 Free PMC article.
29 results